Vision-Sciences (VSCI) 0.47 $VSCI
Vision-Sciences' (VSCI) CEO Howard Zauberman on Q3 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 05, 11:22AM CST
VSCI: 0.47 (unch)
Vision-Sciences reports FQ3 earnings
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 3:35PM CST
VSCI: 0.47 (unch)
Vision-Sciences Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2015
Marketwired - Wed Feb 04, 3:15PM CST
Vision-Sciences, Inc. (NASDAQ: VSCI), a leading provider of unique flexible endoscopic products, today announced financial results for the three- and nine-month periods ended December 31, 2014.
VSCI: 0.47 (unch)
INVESTOR ALERT: Levi & Korsinsky, LLP Commences an Investigation of the Board of Directors of Vision-Sciences, Inc. In Connection With the Fairness of the Merger of the Company to Uroplasty, Inc.
Business Wire - Mon Feb 02, 2:57PM CST
Levi & Korsinsky is commencing an investigation into the Board of Directors of Vision-Sciences, Inc. ("Vision-Sciences" or "the Company"
(NasdaqCM:VSCI) in connection with possible breaches of fiduciary duty and other violations of state law in connection with the merger of the Company to Uroplasty, Inc. (NasdaqCM:UPI).
VSCI: 0.47 (unch), UPI: 1.27 (unch)
Merger Arbitrage Mondays - January 26, 2015
Asif Suria - Seeking Alpha - Mon Jan 26, 8:33AM CST
Merger activity decreased last week with one new merger announced and two deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
GFIG: 6.03 (-0.03), TLM: 7.63 (-0.03), NWBI: 11.91 (+0.08), LO: 67.30 (-0.80), URZ: 1.18 (+0.01), BGCP: 9.34 (+0.19), UUUU: 4.93 (-0.02), T: 34.66 (+0.05), DLTR: 76.82 (+0.97), VSCI: 0.47 (unch), DTV: 87.51 (-0.32), UPI: 1.27 (unch), TWC: 149.74 (+2.21), BHI: 64.31 (+1.93), ESYS: 17.46 (+0.01), RAI: 71.86 (-1.23), LNN: 88.94 (-0.02), HAL: 44.19 (+1.42), EDS: 1.55 (+0.01), FDO: 77.86 (+0.31), CYN: 90.32 (+0.49), MRK: 58.81 (-0.07), RY: 62.26 (+0.23), LNBB: 17.74 (-0.01), IGT: 17.20 (-0.04), CMCSA: 59.47 (+1.09)
Vision-Sciences to Host Third Quarter Fiscal 2015 Results Call
ACCESSWIRE - Thu Jan 22, 7:00AM CST
ORANGEBURG, NY / ACCESSWIRE / January 22, 2015 / Vision-Sciences, Inc. (Nasdaq: VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced that the Company will release its financial results for the third quarter fiscal 2015, ended December 31, 2014, after the market closes on Wednesday, February 4, 2015. Howard Zauberman, President and Chief Executive Officer, and Gary Siegel, Vice President, Finance, will host a conference call to discuss the results as follows:
VSCI: 0.47 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Uroplasty, Inc. of Class Action Challenging the Fairness of the Sale of the Company to Vision-Sciences, Inc. -- UPI
GlobeNewswire - Fri Jan 16, 8:58AM CST
Levi & Korsinsky notifies shareholders of Uroplasty, Inc. ("Uroplasty" or "the Company" (Nasdaq:UPI) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Vision-Sciences, Inc. (Nasdaq:VSCI). A complaint was filed in Minnesota state court.
VSCI: 0.47 (unch), UPI: 1.27 (unch)
UPI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc. - UPI
Business Wire - Wed Dec 31, 11:33AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Uroplasty, Inc. (NasdaqCM:UPI) ("Uroplasty" in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM:VSCI).
VSCI: 0.47 (unch), UPI: 1.27 (unch)
Hidden Annualized 66% Return: Uroplasty Inc. And Vision-Sciences To Merge
Maudes Capital - at Seeking Alpha - Mon Dec 29, 12:52PM CST
VSCI: 0.47 (unch), UPI: 1.27 (unch)
Merger Arbitrage Mondays - December 29, 2014
Asif Suria - at Seeking Alpha - Mon Dec 29, 10:06AM CST
Merger activity decreased last week with three new mergers announced and three deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
CACQ: 7.72 (+0.12), PIKE: 12.01 (+0.01), PRLS: 6.96 (-0.02), MGAM: 36.44 (-0.01), VSCI: 0.47 (unch), UPI: 1.27 (unch), CZR: 10.78 (+0.18), OPLK: 24.23 (-0.03), GCA: 6.92 (+0.17)
New Research Study by the Mayo Clinic Finds Sedation-Free TNE With EndoSheath(R) Technology May Provide an Effective Alternative to Standard Upper Endoscopy Procedures
GlobeNewswire - Mon Dec 29, 6:30AM CST
A new peer-reviewed research study published in the American Journal of Gastroenterology concludes sedation-free transnasal esophagoscopy (TNE) may provide an effective alternative strategy to conventional sedated esophagogastroduodenoscopy (EGD) for esophageal assessment and Barrett's Esophagus (BE) screening for patients. The research trial was conducted by gastroenterologists at the Mayo Clinic utilizing the Vision Sciences Transnasal Esophagoscope with EndoSheath Technology and evaluated over 200 patients in both a clinic setting and in the community as part of the health system's mobile research program.
VSCI: 0.47 (unch)
UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc.
Business Wire - Wed Dec 24, 11:19AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company" (NasdaqCM: UPI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM: VSCI).
VSCI: 0.47 (unch), UPI: 1.27 (unch)
UROPLASTY, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Vision-Sciences, Inc.
Business Wire - Tue Dec 23, 10:40AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Uroplasty, Inc. ("Uroplasty" (NASDAQ: UPI) concerning the sale to Vision-Sciences, Inc. (NasdaqCM: VSCI). Under the terms of the agreement, Uroplasty shareholders will receive 3.6331 shares of VSCI for each share owned. Based on the closing price of both stocks before the deal was announced, the consideration is valued at approximately $3.67, which is only a 15.6% premium and significantly lower than the 52-week high. Also, at least one analyst estimated a value of $6.00 per share.
VSCI: 0.47 (unch), UPI: 1.27 (unch)
UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc. -- UPI
PR Newswire - Tue Dec 23, 10:22AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company" (NasdaqCM: UPI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM: VSCI).
VSCI: 0.47 (unch), UPI: 1.27 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:50AM CST
ADXS: 7.18 (+0.06), SANW: 4.80 (+0.19), ASPS: 22.32 (+0.09), OCN: 9.10 (+0.09), ZAZA: 2.17 (+0.08), SGOC: 0.56 (-0.03), AAMC: 173.53 (-8.22), VOC: 5.77 (+0.31), TECU: 3.07 (-0.02), RDUS: 50.37 (+0.63), IRMD: 14.61 (-0.35), SKYS: 10.55 (-0.65), VSCI: 0.47 (unch), CALA: 16.11 (+0.62), REXX: 5.08 (+0.13), CFRX: 4.00 (-0.06), TRXC: 2.86 (-0.11), CHNR: 1.91 (+0.01), CNET: 1.58 (+0.02), DRYS: 1.01 (+0.02)
UROPLASTY, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Dec 22, 11:42AM CST
Rigrodsky & Long, P.A.:
VSCI: 0.47 (unch), UPI: 1.27 (unch)
UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc.
Business Wire - Mon Dec 22, 9:42AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company" (NasdaqCM: UPI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM: VSCI).
VSCI: 0.47 (unch), UPI: 1.27 (unch)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 8:17AM CST
OCN: 9.10 (+0.09), SGOC: 0.56 (-0.03), NVGN: 2.79 (+0.17), EXAS: 25.56 (-0.54), TGE: 1.95 (-0.10), CZR: 10.78 (+0.18), ENTA: 33.30 (-0.44), NQ: 3.95 (-0.03), PVG: 6.44 (-0.07), RDUS: 50.37 (+0.63), CANF: 3.85 (+0.05), NG: 3.96 (+0.03), SYN: 2.13 (+0.18), GILD: 101.90 (+1.10), VSCI: 0.47 (unch), CNET: 1.58 (+0.02), SVM: 1.38 (+0.04)
Vision-Sciences' (VSCI) CEO Howard Zauberman on Q3 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 05, 11:22AM CST
VSCI: 0.47 (unch)
Vision-Sciences reports FQ3 earnings
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 3:35PM CST
VSCI: 0.47 (unch)
Vision-Sciences Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2015
Marketwired - Wed Feb 04, 3:15PM CST
Vision-Sciences, Inc. (NASDAQ: VSCI), a leading provider of unique flexible endoscopic products, today announced financial results for the three- and nine-month periods ended December 31, 2014.
VSCI: 0.47 (unch)
INVESTOR ALERT: Levi & Korsinsky, LLP Commences an Investigation of the Board of Directors of Vision-Sciences, Inc. In Connection With the Fairness of the Merger of the Company to Uroplasty, Inc.
Business Wire - Mon Feb 02, 2:57PM CST
Levi & Korsinsky is commencing an investigation into the Board of Directors of Vision-Sciences, Inc. ("Vision-Sciences" or "the Company"
(NasdaqCM:VSCI) in connection with possible breaches of fiduciary duty and other violations of state law in connection with the merger of the Company to Uroplasty, Inc. (NasdaqCM:UPI). VSCI: 0.47 (unch), UPI: 1.27 (unch)
Merger Arbitrage Mondays - January 26, 2015
Asif Suria - Seeking Alpha - Mon Jan 26, 8:33AM CST
Merger activity decreased last week with one new merger announced and two deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
GFIG: 6.03 (-0.03), TLM: 7.63 (-0.03), NWBI: 11.91 (+0.08), LO: 67.30 (-0.80), URZ: 1.18 (+0.01), BGCP: 9.34 (+0.19), UUUU: 4.93 (-0.02), T: 34.66 (+0.05), DLTR: 76.82 (+0.97), VSCI: 0.47 (unch), DTV: 87.51 (-0.32), UPI: 1.27 (unch), TWC: 149.74 (+2.21), BHI: 64.31 (+1.93), ESYS: 17.46 (+0.01), RAI: 71.86 (-1.23), LNN: 88.94 (-0.02), HAL: 44.19 (+1.42), EDS: 1.55 (+0.01), FDO: 77.86 (+0.31), CYN: 90.32 (+0.49), MRK: 58.81 (-0.07), RY: 62.26 (+0.23), LNBB: 17.74 (-0.01), IGT: 17.20 (-0.04), CMCSA: 59.47 (+1.09)
Vision-Sciences to Host Third Quarter Fiscal 2015 Results Call
ACCESSWIRE - Thu Jan 22, 7:00AM CST
ORANGEBURG, NY / ACCESSWIRE / January 22, 2015 / Vision-Sciences, Inc. (Nasdaq: VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced that the Company will release its financial results for the third quarter fiscal 2015, ended December 31, 2014, after the market closes on Wednesday, February 4, 2015. Howard Zauberman, President and Chief Executive Officer, and Gary Siegel, Vice President, Finance, will host a conference call to discuss the results as follows:
VSCI: 0.47 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Uroplasty, Inc. of Class Action Challenging the Fairness of the Sale of the Company to Vision-Sciences, Inc. -- UPI
GlobeNewswire - Fri Jan 16, 8:58AM CST
Levi & Korsinsky notifies shareholders of Uroplasty, Inc. ("Uroplasty" or "the Company"
(Nasdaq:UPI) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Vision-Sciences, Inc. (Nasdaq:VSCI). A complaint was filed in Minnesota state court. VSCI: 0.47 (unch), UPI: 1.27 (unch)
UPI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc. - UPI
Business Wire - Wed Dec 31, 11:33AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Uroplasty, Inc. (NasdaqCM:UPI) ("Uroplasty"
in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM:VSCI). VSCI: 0.47 (unch), UPI: 1.27 (unch)
Hidden Annualized 66% Return: Uroplasty Inc. And Vision-Sciences To Merge
Maudes Capital - at Seeking Alpha - Mon Dec 29, 12:52PM CST
VSCI: 0.47 (unch), UPI: 1.27 (unch)
Merger Arbitrage Mondays - December 29, 2014
Asif Suria - at Seeking Alpha - Mon Dec 29, 10:06AM CST
Merger activity decreased last week with three new mergers announced and three deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
CACQ: 7.72 (+0.12), PIKE: 12.01 (+0.01), PRLS: 6.96 (-0.02), MGAM: 36.44 (-0.01), VSCI: 0.47 (unch), UPI: 1.27 (unch), CZR: 10.78 (+0.18), OPLK: 24.23 (-0.03), GCA: 6.92 (+0.17)
New Research Study by the Mayo Clinic Finds Sedation-Free TNE With EndoSheath(R) Technology May Provide an Effective Alternative to Standard Upper Endoscopy Procedures
GlobeNewswire - Mon Dec 29, 6:30AM CST
A new peer-reviewed research study published in the American Journal of Gastroenterology concludes sedation-free transnasal esophagoscopy (TNE) may provide an effective alternative strategy to conventional sedated esophagogastroduodenoscopy (EGD) for esophageal assessment and Barrett's Esophagus (BE) screening for patients. The research trial was conducted by gastroenterologists at the Mayo Clinic utilizing the Vision Sciences Transnasal Esophagoscope with EndoSheath Technology and evaluated over 200 patients in both a clinic setting and in the community as part of the health system's mobile research program.
VSCI: 0.47 (unch)
UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc.
Business Wire - Wed Dec 24, 11:19AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company"
(NasdaqCM: UPI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM: VSCI). VSCI: 0.47 (unch), UPI: 1.27 (unch)
UROPLASTY, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Vision-Sciences, Inc.
Business Wire - Tue Dec 23, 10:40AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Uroplasty, Inc. ("Uroplasty"
(NASDAQ: UPI) concerning the sale to Vision-Sciences, Inc. (NasdaqCM: VSCI). Under the terms of the agreement, Uroplasty shareholders will receive 3.6331 shares of VSCI for each share owned. Based on the closing price of both stocks before the deal was announced, the consideration is valued at approximately $3.67, which is only a 15.6% premium and significantly lower than the 52-week high. Also, at least one analyst estimated a value of $6.00 per share. VSCI: 0.47 (unch), UPI: 1.27 (unch)
UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc. -- UPI
PR Newswire - Tue Dec 23, 10:22AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company"
(NasdaqCM: UPI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM: VSCI). VSCI: 0.47 (unch), UPI: 1.27 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:50AM CST
ADXS: 7.18 (+0.06), SANW: 4.80 (+0.19), ASPS: 22.32 (+0.09), OCN: 9.10 (+0.09), ZAZA: 2.17 (+0.08), SGOC: 0.56 (-0.03), AAMC: 173.53 (-8.22), VOC: 5.77 (+0.31), TECU: 3.07 (-0.02), RDUS: 50.37 (+0.63), IRMD: 14.61 (-0.35), SKYS: 10.55 (-0.65), VSCI: 0.47 (unch), CALA: 16.11 (+0.62), REXX: 5.08 (+0.13), CFRX: 4.00 (-0.06), TRXC: 2.86 (-0.11), CHNR: 1.91 (+0.01), CNET: 1.58 (+0.02), DRYS: 1.01 (+0.02)
UROPLASTY, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Dec 22, 11:42AM CST
Rigrodsky & Long, P.A.:
VSCI: 0.47 (unch), UPI: 1.27 (unch)
UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc.
Business Wire - Mon Dec 22, 9:42AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company"
(NasdaqCM: UPI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM: VSCI). VSCI: 0.47 (unch), UPI: 1.27 (unch)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 8:17AM CST
OCN: 9.10 (+0.09), SGOC: 0.56 (-0.03), NVGN: 2.79 (+0.17), EXAS: 25.56 (-0.54), TGE: 1.95 (-0.10), CZR: 10.78 (+0.18), ENTA: 33.30 (-0.44), NQ: 3.95 (-0.03), PVG: 6.44 (-0.07), RDUS: 50.37 (+0.63), CANF: 3.85 (+0.05), NG: 3.96 (+0.03), SYN: 2.13 (+0.18), GILD: 101.90 (+1.10), VSCI: 0.47 (unch), CNET: 1.58 (+0.02), SVM: 1.38 (+0.04)
